

Supporting Information


Click Pt(IV)-carbohydrates pro-drugs for treatment of osteosarcoma

Eoin Moynihan, Giada Bassi, Andrea Ruffini, Silvia Panseri, Monica Montesi² Trinidad Velasco Torrijos, Diego Montagner


NMR, HR-MS and HPLC

Compound 9


¹H NMR




^{13}C NMR




COSY




HSQC



HMBC





HR-MS




Compound 10


^1H NMR




^{13}C NMR




COSY




HSQC



HMBC




HR-MS




Compound 17


^1H NMR




^{13}C NMR




COSY




HSQC



HMBC




HR-MS




Compound 18


^1H NMR




^{13}C NMR




COSY




HSQC



HMBC




HR-MS




Compound 11


^1H NMR




^{13}C NMR




COSY




HSQC



HMBC




HR-MS




Compound 12


^1H NMR




^{13}C NMR




COSY




HSQC



HMBC




HR-MS




Compound 19


^1H NMR




^{13}C NMR




COSY




HSQC



HMBC




HR-MS




Compound 20


^1H NMR




^{13}C NMR




COSY




HSQC



HMBC




HR-MS




Complex 1


^1H NMR




^{13}C NMR




COSY




HSQC




HMBC



¹⁹⁵Pt NMR




HR-MS




Complex 2


^1H NMR




^{13}C NMR




COSY




HSQC




HMBC



¹⁹⁵Pt NMR




HR-MS




Complex 3


^1H NMR




^{13}C NMR




COSY




HSQC




HMBC



¹⁹⁵Pt NMR




HR-MS




Complex 4


HPLC. Chromatograms of complex 4 in DMSO/HEPES (pH 6.8): a) $t = 0$ minutes; b) after one week at r.t.




^1H NMR




^{13}C NMR




COSY



HSQC




HMBC





^{195}Pt NMR

-087/1536



HR-MS



Dose-response curves used to generate IC_{50} for cisplatin and complexes **1-4** inhibitor activity on viability of SAOS-2 (1), U-2 OS (2) and MG63 (3) cell lines. Log[concentration] in μM and the normalized response (%) of survival fraction of cells are reported on X and Y axes, respectively. 50% survival cells is highlighted in Y dotted line. For each cell line, curves interpolation with 50% survival cells correspond to LogIC_{50} of each drug. Data are reported in the graph as mean \pm standard deviation. For IC_{50} values see table 1.